All In Biotech

Drug Trial Radar · NCT06497465

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Dolutegravir Plus Lamivudine (DTG/3TC) Dual Therapy Versus Dolutegravir With TDF-lamivudine (DTG + TDF/3TC) Among Antiretroviral naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 18, 2025

Primary completion

Jan 31, 2028

Study completion Jan 31, 2029

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ViiV Healthcare
First posted
Jul 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice daily or DTG/3TC ( Dovato) in the morning +dolutegravir (DTG) in the evening, versus standard of care (SOC) twice-daily dolutegravir plus 2 once-daily Nucleoside reverse-transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate /lamivudine (TDF/3TC), among antiretroviral therapy (ART)-nave individuals with HIV-1 receiving rifampin-based TB therapy

Conditions

  • Tuberculosis
  • HIV

Interventions

  • Dolutegravir 50mg TabDrug

    Participants will receive Dolutegravir 50mg

  • Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]Drug

    Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]

  • Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)Drug

    Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Among treatment-naïve participants with HIV-1 who are taking rifampin-based regimens for TB, determine the proportion with HIV-1 virologic suppression (via FDA snapshot algorithm) at 28 weeks of HIV treatment, by armTime frame: 28 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto Tropical de Doenças Infecciosas Manaus

    Manaus, Amazonas, Brazil · Recruiting

  • Universidade Federal da Bahia

    Salvador, Estado de Bahia, Brazil · Recruiting

  • FIOCruz

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Hospital Geral de Nova Iguaçu

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • CePClin - Center for Studies and Research in Infectious Diseases Ltda

    Natal, Rio Grande do Norte, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.